Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma

Abstract The incidence and mortality of hepatocellular carcinoma (HCC) are on a rise in the Western countries including US, attributed mostly to late detection. Sorafenib has been the first-line FDA-approved drug for advanced unresectable HCC for almost a decade, but with limited efficacy due to the...

Full description

Bibliographic Details
Main Authors: Kanchan Vishnoi, Rong Ke, Navin Viswakarma, Piush Srivastava, Sandeep Kumar, Subhasis Das, Sunil Kumar Singh, Daniel R. Principe, Ajay Rana, Basabi Rana
Format: Article
Language:English
Published: Nature Publishing Group 2022-07-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05022-1

Internet

https://doi.org/10.1038/s41419-022-05022-1

Similar Items